Validation of Betalactam ML Prediction Models - TDMAide

Infections Clinical Trial

— TDMAide  

Official title:

Validation of Uncertainty Quantifying Machine Learning Models to Predict Beta-lactam Antimicrobial Concentrations in ICU Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06026852
• Other study ID #: CIV-23-04-042892
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 26, 2024
• Est. completion date: May 31, 2025

Study information

• Verified date: June 2024
• Source: University Hospital, Ghent
• Contact: Thomas De Corte, MD
• Phone: 0032093324134
• Email: thomas.decorte[@]uzgent.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to learn about the real wold behavior of developed machine learning models that predict the plasma concentration of piperacillin-tazobactam and meropenem in critically ill patients admitted to the intensive care unit (ICU).

The main aim of the study is to validate the performance of these machine learning models. To this end, daily measured plasma concentrations of the investigated antimicrobials will be compared with the predicted concentration by the machine learning algorithms.

Additional goals of the study include:

• To describe the total plasma concentration over time of piperacillin-tazobactam and meropenem in patients admitted to the ICU.

• To quantify the correlation between plasma concentrations of piperacillin-tazobactam and meropenem and the development of side effects.

• To evaluate the perceived necessity of therapeutic drug monitoring (TDM) of consultants and physicians in training working in the ICU.

• To evaluate the perceived added value of daily TDM.

Samples (where possible taken routinely) from participating patients will be analyzed for meropenem and piperacillin-tazobactam plasma concentration. Participating physicians will be asked to fill in a short daily questionnaire during the time a patient under their care is treated with the antimicrobial under investigation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 600
• Est. completion date: May 31, 2025
• Est. primary completion date: May 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Patients

Inclusion Criteria:

• Admission to the ICU.

• Age above 18 years old.

• Treatment with piperacillin-tazobactam or meropenem for less than 48 hours.

Exclusion Criteria:

• Pregnant or lactating patients.

• Limitation of therapy beyond "Do not resuscitate".

• Expected demise within 48 hours after inclusion.

• Haemoglobin < 7 g/dL.

• Previous inclusion in this study for a treatment course with the same antimicrobial.

Consultants and physicians in training

Inclusion Criteria:

• Consultant or physician in training working in the ICU.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Infections

Intervention

Device:
• Prediction of plasma concentration of piperacillin-tazobactam or meropenem
For included patients, a prediction will be made by developed machine learning models about the expected plasma concentration of piperacillin-tazobactam or meropenem by using routinely collected health care data.

Diagnostic Test:
• Determination of plasma concentration of piperacillin-tazobactam or meropenem
For included patients, the total plasma concentration of piperacillin-tazobactam or meropenem will be determined. Were possible, this will be done using a blood sample that was collected during routine daily bloodwork which is performed in the morning. If no routine sample is available, a study specific sample will be drawn at approximately the same time as a routine sample would be drawn.

Other:
• Daily short questionnaire
Physicians who care for patients included in the study will be asked to fill in a short daily questionnaire that evaluates the perceived necessity and added value of daily therapeutic drug monitoring.

Locations

Country	Name	City	State
Belgium	University Hospital, Ghent	Ghent

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Ghent	Imec, Research Foundation Flanders

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference between predicted (TDMAIde) and measured (via HPLC-MS/MS method) plasma concentrations	The difference between the predicted concentration (from the TDMAide software) and the concentration range based on the measured concentration (measured from the blood sample from the patient and analyzed using a HPLC-MS/MS method, with and without taking into account intra- and inter measurement variabilities of the HPLC-MS/MS method.	Through study completion, an average of 1 year
Secondary	Plasma concentration (determined via HPLC-MS/MS) trends	Trends in total plasma concentration over time of piperacillin-tazobactam and meropenem in patients admitted to the ICU	Through study completion, an average of 1 year
Secondary	Correlation between plasma concentrations (measured by HPLC-MS/MS) and side effects as percentage of patients experiencing the side effect	The correlation between plasma concentrations of piperacillin-tazobactam and meropenem and the development of renal (decline in urinary output, rise in serum creatinin), gastro-intestinal (C. difficile infections, stool consistency, elevation of ALT/AST/gamma GT/Alkalic fosfatase/INR/APTT/bilirubin), neurological (delirium as measured by Intensice Care Delirium Screening Checklist - ICDSC) or hematological (Rise or fall of thrombocytes, development of leucopenia/agranulocytosis/eosinophelia/hemolytic anemia) side effects.	Through study completion, an average of 1 year
Secondary	Perceived necessity of therapeutic drug monitoring	The perceived necessity of therapeutic drug monitoring of consultants and physicians in training working in the ICU by evaluating the perceived necessity collected during the surveys with the measured plasma concentrations.	Through study completion, an average of 1 year
Secondary	Perceived added value of therapeutic drug monitoring	The perceived added value of daily therapeutic drug monitoring from the responses to the survey	Through study completion, an average of 1 year